"Psoriasis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.
| Descriptor ID |
D011565
|
| MeSH Number(s) |
C17.800.859.675
|
| Concept/Terms |
Pustulosis of Palms and Soles- Pustulosis of Palms and Soles
- Pustulosis Palmaris et Plantaris
- Palmoplantaris Pustulosis
- Pustular Psoriasis of Palms and Soles
|
Below are MeSH descriptors whose meaning is more general than "Psoriasis".
Below are MeSH descriptors whose meaning is more specific than "Psoriasis".
This graph shows the total number of publications written about "Psoriasis" by people in this website by year, and whether "Psoriasis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 3 | 4 |
| 1999 | 3 | 0 | 3 |
| 2002 | 2 | 0 | 2 |
| 2003 | 8 | 0 | 8 |
| 2004 | 4 | 0 | 4 |
| 2005 | 9 | 0 | 9 |
| 2006 | 10 | 0 | 10 |
| 2007 | 9 | 0 | 9 |
| 2008 | 10 | 1 | 11 |
| 2009 | 7 | 1 | 8 |
| 2010 | 8 | 1 | 9 |
| 2011 | 8 | 1 | 9 |
| 2012 | 6 | 2 | 8 |
| 2013 | 8 | 1 | 9 |
| 2014 | 8 | 0 | 8 |
| 2015 | 5 | 1 | 6 |
| 2016 | 12 | 1 | 13 |
| 2017 | 14 | 0 | 14 |
| 2018 | 23 | 0 | 23 |
| 2019 | 14 | 0 | 14 |
| 2020 | 14 | 1 | 15 |
| 2021 | 8 | 0 | 8 |
| 2022 | 7 | 0 | 7 |
| 2023 | 7 | 0 | 7 |
| 2024 | 7 | 1 | 8 |
| 2025 | 5 | 0 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Psoriasis" by people in Profiles.
-
Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb Studies. Am J Clin Dermatol. 2025 Nov; 26(6):967-979.
-
Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flares. J Clin Invest. 2025 Sep 02; 135(17).
-
Combined Dermatology/Rheumatology Clinics for Management of Psoriatic Disease: Current State. Rheum Dis Clin North Am. 2025 08; 51(3):537-544.
-
Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial. J Am Acad Dermatol. 2025 Sep; 93(3):644-653.
-
Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: Post hoc analysis of the EFFISAYIL 2 study. J Am Acad Dermatol. 2025 Jun; 92(6):1235-1242.
-
Sequencing of Targeted Therapy in Psoriasis: Does it Matter? Am J Clin Dermatol. 2024 Sep; 25(5):795-810.
-
Active biointegrated living electronics for managing inflammation. Science. 2024 05 31; 384(6699):1023-1030.
-
Inhibition of oxidized low-density lipoprotein with orticumab inhibits coronary inflammation and reduces residual inflammatory risk in psoriasis: a pilot randomized, double-blind placebo-controlled trial. Cardiovasc Res. 2024 05 29; 120(7):678-680.
-
Bimekizumab for the treatment of psoriasis. Immunotherapy. 2024 04; 16(7):431-446.
-
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials. Br J Dermatol. 2024 03 15; 190(4):477-485.